Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to provide expanded access of givosiran to patients with Acute Hepatic Porphyria (AHP).


Clinical Trial Description

Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact the study research staff using the Contacts provided. For general information, see the link provided in More Information. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04056481
Study type Expanded Access
Source Alnylam Pharmaceuticals
Contact
Status Approved for marketing
Phase

See also
  Status Clinical Trial Phase
Completed NCT03338816 - ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) Phase 3
Terminated NCT03547297 - INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
Not yet recruiting NCT04923516 - Prevalence of Acute Hepatic Porphyria
Recruiting NCT05344599 - Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome
Completed NCT02240784 - EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)
Recruiting NCT04883905 - ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)